Zomedica to Present at 30th Annual ROTH Conference

ANN ARBOR, Mich., March 07, 2018 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced that it will present at the 30th Annual ROTH Conference on March 13, 2018 in Dana Point, CA.

Chief Executive Officer Gerald Solensky, Jr. will provide an overview of Zomedica’s business during his live presentation and will be available to participate in one-on-one meetings with investors registered to attend the conference.

30th Annual ROTH ConferenceDate: Tuesday, March 13, 2018Time: 2:30 p.m. PDTLocation: The Ritz-Carlton Laguna Nigel, Dana Point, CA

Investors and other interested parties will be able to access a live webcast of the presentation by visiting Zomedica’s website at http://investors.zomedica.com. A replay of the webcast will be accessible on the Zomedica website following the event.

About ZomedicaBased in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) (TSX-V: ZOM) is a veterinary diagnostic and pharmaceutical and company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.

Follow Zomedica

• Email Alerts: http://investors.zomedica.com
• LinkedIn: https://www.linkedin.com/company/zomedica
• Facebook: https://www.facebook.com/zomedica/
• Twitter: https://twitter.com/zomedica

Reader AdvisoryNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

Investor Relations ContactsShameze Rampertab, CPA, CA[email protected]+1 647.283.3630

PCG Advisory GroupKirin Smith, COO[email protected]+1 646.863.6519www.pcgadvisory.com

Media ContactAndrea Eberle[email protected]+1 734.369.2555

Source: Zomedica Pharmaceuticals Corp.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Merck and Moderna's melanoma drug combo beats Keytruda alone in trial
• UAV Magnetic Survey Reveals Untested Convergence Zone at AZ Copper-Gold Project
• UraniumX Completes Acquisition of the Dieter Lake Uranium Project; IsoEnergy Becomes Strategic Shareholder